Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV
Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
The main aims of the study are to assess the safety, pharmacokinetics and antiviral activity
of multiple doses of RV521 compared to placebo in healthy adult subjects infected with
Respiratory Syncytial Virus (RSV) in the Virus Challenge Model